ALECENSA (Roche Products Pty Ltd)
Product name
ALECENSA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
223 (255 working days)
Active ingredients
alectinib hydrochloride
Registration type
EOI
Indication
Adjuvant treatment of resected non-small cell lung cancer
Alecensa is indicated as adjuvant treatment in adult patients following tumour resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥ 4 cm or node positive).